AUSTIN, Texas and MCLEAN, Va., July 22,
2020 /PRNewswire/ -- Appian (NASDAQ: APPN) and Everlywell,
the digital health company offering consumers access to at-home lab
tests, are working together to support safe and healthy returns to
the workplace and to campus for corporations and higher education
institutions. The two companies have signed a partnership
integrating Everlywell's at-home collection COVID-19 testing within
the Appian Workforce Safety and Appian CampusPass™ solutions.
"Everlywell was founded to give people access to high-quality
lab tests that can be taken at home. With the pandemic continuing
around us, our mission has never been more important," said
Julia Cheek, founder and CEO of
Everlywell. "We are proud to support Appian's corporate and
academic customers in providing FDA-authorized COVID-19 testing to
help keep their students, staff, and customers safe."
Through the partnership, people using Appian's return-to-site
solutions will be able to request home delivery of Everlywell's
COVID-19 Test Home Collection Kit by taking a simple screening
questionnaire based on CDC guidelines. Each test request will be
reviewed by an independent physician from Everlywell's third-party
telehealth partner. Test results will be delivered to the
test-taker's mobile device in as little as 24-48 hours of the
sample arriving at an authorized lab. Everlywell's product and its
laboratory partners have received Emergency Use Authorization from
the U.S. Food and Drug Administration (FDA). The assays used by
Everlywell and its lab partners meet or exceed the FDA's
performance criteria for COVID-19 test accuracy, and telehealth
consultations are included for those with positive results.
Test results can be used in Appian's screening, contact tracing,
and isolation processes to maintain the health of reopened
workplaces and campuses. Appian is the only enterprise software
provider offering the integration of testing within a holistic
COVID-19 return-to-workplace and return-to-campus solution.
Appian's Workforce Safety and CampusPass solutions are the
fastest way to safely coordinate the return of the entire workforce
and academic communities. The holistic offerings centralize and
automate all the key components needed for safe on-site returns.
The solutions, built on the Appian Low-code Automation Platform,
deliver:
- An integrated and seamless experience to process health
screenings, return-to-site authorizations, contact tracing,
isolation processing, and now, COVID-19 testing.
- The deployment speed needed to be up-and-running in a matter of
days, and the flexibility for easy changes via a user interface
without IT intervention.
- The data protection and security of Appian's HIPAA-compliant
and HiTRUST-certified cloud, and enabling GDPR and FERPA
compliance.
"Businesses and academic institutions will be conducting
frequent testing within their communities, and our partnership with
Everlywell makes that process fast, integrated, and secure," said
Matt Calkins, CEO of Appian.
For more information on Appian's COVID-19 solutions, visit
https://www.appian.com/workforce-safety/ and
https://www.appian.com/campuspass/.
About Appian
Appian provides a low-code automation
platform that accelerates the creation of high-impact business
applications. Many of the world's largest organizations use Appian
applications to improve customer experience, achieve operational
excellence, and simplify global risk management and compliance. For
more information, visit www.appian.com.
About Everlywell
Everlywell believes consumers
deserve access to affordable lab tests and insightful,
digitally-enabled results with actionable next steps. The company
connects consumers to lab partners offering a suite of validated
lab tests including Cholesterol, Heart Health, Fertility, STIs,
Lyme Disease, Testosterone, Thyroid and more. Prices are
straightforward starting at $49 and
tests are generally covered by Flexible Spending and Health Savings
Accounts. Physician-reviewed, actionable test results from
CLIA-certified labs are provided within days of sample receipt. The
company also provides testing for health plans, healthcare
organizations, and employers, including some of the largest health
plans in the nation.
The Austin-based company was
founded in 2015 and is advised by a Scientific Advisory Board
that includes some of the nation's top scientists from Harvard, MIT, Google
and NYU. Everlywell was selected as one
of Fast Company's Most Innovative Companies in 2019.
For more information please visit www.everlywell.com.
Important information about the Everlywell Test Home
Collection Kit:
Everlywell's home collection kit is
FDA-authorized under the Emergency Use Authorization framework. It
has not been FDA-cleared or approved. Everlywell's home collection
kit has been authorized only for the home collection and
maintenance of nasal swab specimens as an aid in detection of
nucleic acid from SARS-CoV-2, not for any other viruses or
pathogens. Everlywell's home collection kit in combination with the
authorized test is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostic tests for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.
§ 360bbb-3(b)(1), unless the authorization is terminated or revoked
sooner.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/appian-and-everlywell-partner-to-support-safe-workplace-and-campus-returns-through-integrated-covid-19-testing-301097843.html
SOURCE Appian